The Company Strengthens Balance Sheet, Takes Strides to Regaining Nasdaq Listing Compliance
Center for Biologics Evaluation and Research has chosen mRNA-3705 as one of four investigational medicines for accelerated development to address unmet medical needs for rare diseases